Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]

Combination of dalantercept plus axitinib versus placebo plus axitinib in...

Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma ( Dr Martin Voss - Memorial Sloan Kettering Cancer Centre, New York City, USA )

VEGF targeted therapy and chemo an active combination in rapidly progressive...

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )

Impact of statins on survival outcomes in metastatic renal cell carcinoma

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA

Impact of statins on survival outcomes in metastatic renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )

Genomic profiling may reveal new drug targets in urothelial carcinoma

Dr Jeffrey Ross - Albany Medical College, Albany, USA

Genomic profiling may reveal new drug targets in urothelial carcinoma ( Dr Jeffrey Ross - Albany Medical College, Albany, USA )

Combination of abiraterone and cabazitaxel in metastatic castration-resistant...

Dr Joaquin Mateo - Institute of Cancer Research, London, UK

Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer ( Dr Joaquin Mateo - Institute of Cancer Research, London, UK )

When and whether to conduct endocrine therapy in non-metastatic prostate cancer

Dr Frederik Birkebæk Thomsen - University of Copenhagen, Copenhagen, Denmark

When and whether to conduct endocrine therapy in non-metastatic prostate cancer ( Dr Frederik Birkebæk Thomsen - University of Copenhagen, Copenhagen, Denmark )

ASCO GU 2015: Review of the latest data in prostate cancer

Prof Eleni Efstathiou, Prof Charles Ryan, Dr Heather Payne

ASCO GU 2015: Review of the latest data in prostate cancer ( Prof Eleni Efstathiou, Prof Charles Ryan, Dr Heather Payne )

Combination of pazopanib and paclitaxel safe in urothelial cancer

Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA

Combination of pazopanib and paclitaxel safe in urothelial cancer ( Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA )

Tackling renal cancer with a combination of autologous immunotherapy and...

Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA

Tackling renal cancer with a combination of autologous immunotherapy and sunitinib ( Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA )

ASCO GU 2015: Prostate highlights from day one

Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin

ASCO GU 2015: Prostate highlights from day one ( Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin )

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer

Prof Thomas Powles - Barts Health, London, UK

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer ( Prof Thomas Powles - Barts Health, London, UK )

Metastatic prostate cancer - Interpreting negative trial results

Prof Stephane Oudard and Prof Noel Clarke

Metastatic prostate cancer - Interpreting negative trial results ( Prof Stephane Oudard and Prof Noel Clarke )

More from ecancer